Modified Cued Recall Test: Longitudinal Analysis of Test Versions and Item Recall in Adults With Down Syndrome.

Leptin levels are associated with body mass index and Alzheimer's disease in Down syndrome.

Joint spatial associations of amyloid beta and tau pathology in Down syndrome and preclinical Alzheimer's disease: Cross-sectional associations with early cognitive impairments.

Targeting Artemis Sensitizes B Cells to Topoisomerase 2 Poisons by Disrupting DNA-PKcs-Dependent Repair.

Longitudinal study of body mass index in relation to Alzheimer's disease pathology and symptomatology in Down syndrome.

Cognitive and Behavioural Associations of Visual and Hearing Impairments Across the Lifespan in People With Down Syndrome, a Scoping Review.

The Alzheimer's Biomarker Consortium-Down Syndrome (ABC-DS): A 10-year report.

Correlating hippocampal and amygdala volumes with neuropathological burden in Down syndrome and Alzheimer's disease and related neurodegenerative pathologies using 7T postmortem MRI.

Behavioral and psychological symptoms of dementia and Alzheimer's disease progression in Down syndrome.

Resistance and resilience to Alzheimer's disease in Down syndrome.

Longitudinal investigation of gait and Alzheimer's disease in adults with Down syndrome.

23ME-01473, an Fc Effector-Enhanced Anti-ULBP6/2/5 Antibody, Restores NK Cell-Mediated Antitumor Immunity through NKG2D and FcÎłRIIIa Activation.

A neuropathology case report of a woman with Down syndrome who remained cognitively stable: Implications for resilience to neuropathology.

First-in-Human Study of 23ME-00610, an Antagonistic Antibody for Genetically Validated CD200R1 Immune Checkpoint, in Participants with Advanced Solid Malignancies.

Timeline to symptomatic Alzheimer's disease in people with Down syndrome as assessed by amyloid-PET and tau-PET: a longitudinal cohort study.